Sector News

Would Teva buy Korea's Celltrion to beef up in biosimilars?

October 17, 2016
Life sciences

Earlier this month, Teva agreed to pick up U.S. and Canadian rights to a pair of biosims from Korea’s Celltrion. But it might not stop with just two.

The generics giant may consider purchasing the Korean drugmaker itself, a Teva spokesman told Korean news source The Investor.

“We will continue to investigate such opportunities as we balance risk and seek complementary skills in our partners,” he said.

It’s not the first time the idea has come up. Back in early 2014, when Celltrion was planning to sell a controlling stake in the company, Teva’s name popped up in deal rumors–along with those of peers AstraZeneca and Roche.

Why all the interest? Celltrion’s biosim plans are beginning to come to fruition. Along with partner Pfizer, it already boasts an FDA-approved copy of Johnson & Johnson blockbuster Remicade waiting for the green light to launch in the U.S.

And there’s more where that came from. It’s working on versions of Roche oncology giants Rituxan and Herceptin, too–and it granted Teva North American rights to those biosims in a $160 million pact sealed in early October.

Teva CEO Erez Vigodman in particular has highlighted biosimilars as a key component of the Israeli drugmaker’s strategy. But the company has already struck out once in the field: In 2013, one-time biosim partner Lonza backed out of the pair’s 2009 agreement after development and marketing costs piled up.

Meanwhile, Vigodman has also been talking up branded buys since Teva wrapped up its $40 billion Allergan generics buyout. Teva will be looking out for “attractive specialty assets, or branded drug assets or pipeline assets” that fit in with the therapeutic areas it’s already tackling, including pain, neurodegenerative disease and respiratory disorders, Vigodman said in August.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.